Everything below concerns GHRH. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-20. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
GM-3009 is a κ-opioid receptor (KOR) agonist and noribogaine analogue which is under development for the treatment of opioid-related disorders. Its route of administration is unspecified. The drug is a highly potent agonist of the human KOR, with an affinity (Ki) of 0.9 nM or 87.3 nM depending on the radioligand and an EC50Tooltip half-maximal effective concentration of 0.8 nM. In contrast to noribogaine, it did not show pro-arrhythmic effects in fresh human ventricular cardiomyocytes ex vivo. GM-3009 produces antinociceptive effects and dose-dependently reduces oxycodone self-administration in rodents. It is being developed by Gilgamesh Pharmaceuticals. As of June 2024, it is in the preclinical research stage of development. The exact chemical structure of GM-3009 does not yet appear to have been disclosed. However, it is known to be an "oxa-iboga" derivative. Oxa-ibogaine analogues have notably been patented and studied by Dalibor Sames and colleagues, with Sames being a co-founder of Gilgamesh Pharmaceuticals.
=== Clinical and translational applications === Much of this methodological work feeds directly into clinical practice: Borchers' laboratory has applied targeted mass spectrometry to cancer biomarkers and precision oncology, and to other clinical questions, including a 2024 study characterizing the proteomic changes from acute to post-acute (long) COVID-19. His group has also investigated targeted proteomics for anti-doping applications, including a project funded by the Partnership for Clean Competition that used longitudinal blood-protein profiling to screen for blood doping. From 2012 he was one of three project leaders, with Andrew Penn and Shelagh Coutts, on a $9.6 million Genome Canada large-scale applied research project that sought to develop a rapid, inexpensive blood test to distinguish transient ischaemic attacks from conditions that mimic them and reduce reliance on neuroimaging. The project produced an electronic triage tool that came into clinical use on Vancouver Island, alongside work on candidate protein biomarkers.
=== Blood supply === The sinoatrial node receives its blood supply from the sinoatrial nodal artery. This blood supply, however, can differ hugely between individuals. For example, in most humans, this is a single artery, although in some cases there have been either 2 or 3 sinoatrial node arteries supplying the SA node. Also, the SA node artery mainly originates as a branch of the right coronary artery; however in some individuals it has arisen from the circumflex artery, which is a branch of the left coronary artery. Finally, the SA node artery commonly passes behind the superior vena cava, before reaching the SA node; however in some instances it passes in front. Despite these many differences, there doesn't appear to be any advantage to how many sinoatrial nodal arteries an individual has, or where they originate.
A potential application for MOFs is biological imaging and sensing via photoluminescence. A large subset of luminescent MOFs use lanthanides in the metal clusters. Lanthanide photoluminescence has many unique properties that make them ideal for imaging applications, such as characteristically sharp and generally non-overlapping emission bands in the visible and near-infrared (NIR) regions of the spectrum, resistance to photobleaching or "blinking", and long luminescence lifetimes. However, lanthanide emissions are difficult to sensitize directly because they must undergo LaPorte forbidden f-f transitions. Indirect sensitization of lanthanide emission can be accomplished by employing the "antenna effect", where the organic linkers act as antennae and absorb the excitation energy, transfer the energy to the excited state of the lanthanide, and yield lanthanide luminescence upon relaxation. A prime example of the antenna effect is demonstrated by MOF-76, which combines trivalent lanthanide ions and 1,3,5-benzenetricarboxylate (btc) linkers to form infinite rod SBUs coordinated into a three dimensional lattice. As demonstrated by multiple research groups, the BTC linker can effectively sensitize the lanthanide emission, resulting in a MOF with variable emission wavelengths depending on the lanthanide identity. Additionally, the Yan group has shown that Eu3+- and Tb3+- MOF-76 can be used for selective detection of acetophenone from other volatile monoaromatic hydrocarbons. Upon acetophenone uptake, the MOF shows a sharp decrease, or quenching, of the luminescence intensity.
Sources: en.wikipedia.org
== See also == Appropriations bill (United States) Continuing resolution Government budget by country I.O.U.S.A., documentary film by Patrick Creadon List of U.S. state budgets Modern Monetary Theory Starve the beast (policy) Unemployment in the United States United States fiscal cliff United States public debt International affairs budget of the United States
Glucocorticoid injections are often used for acute and localized flare-ups. About 0.1% to 0.8% of the population is affected, with onset typically occurring in young adults. While men and women are equally affected with AS, women are more likely to experience inflammation rather than fusion.
, the plot would show a negative spike as temperature increases beyond the melting point, since melting is an endothermic process. Conversely, it would show a positive spike as temperature drops below the melting point. This curve can be used to calculate enthalpies of transitions. This is done by taking the time-integral of peak corresponding to a given transition:
Sources: en.wikipedia.org
Corticotropin-releasing hormone (CRH), which regulates ACTH secretion from the anterior pituitary gland Somatostatin, which regulates growth hormone secretion from the anterior pituitary gland Thyrotropin-releasing hormone (TRH), which regulates TSH and prolactin secretion
==== Before birth ==== Mammary gland development is characterized by the unique process by which the epithelium invades the stroma. The development of the mammary gland occurs mainly after birth. During puberty, tubule formation is coupled with branching morphogenesis which establishes the basic arboreal network of ducts emanating from the nipple. Developmentally, mammary gland epithelium is constantly produced and maintained by rare epithelial cells, dubbed as mammary progenitors which are ultimately thought to be derived from tissue-resident stem cells. Embryonic mammary gland development can be divided into a series of specific stages. Initially, the formation of the milk lines that run between the fore and hind limbs bilaterally on each side of the midline occurs around embryonic day 10.5 (E10.5). The second stage occurs at E11.5 when placode formation begins along the mammary milk line. This will eventually give rise to the nipple. Lastly, the third stage occurs at E12.5 and involves the invagination of cells within the placode into the mesenchyme, leading to a mammary anlage (biology). The primitive (stem) cells are detected in the embryo and their numbers increase steadily during development.
Another glycogen storage disease that affects muscle (muscle GSD); Metabolic myopathy other than glycogen storage disease; Endocrine myopathy that affects carbohydrate metabolism secondary to the primary disease; Inadequate blood flow (ischemia), particularly of the calves Intermittent claudication; Popliteal artery entrapment syndrome; Chronic venous insufficiency. Poor diet or malabsorption disease resulting in malnutrition of micronutrients essential for muscle glycogen metabolism; Other rare myopathies, such as Brody disease, Rippling muscle disease, Erythrocyte lactate transporter defect, a small number of muscular dystrophies, Tubular aggregate myopathy (TAM), etc. Exercise-induced muscle fatigue without cramping:
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.